Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases Hironori Uruga, MD, PhD, Emine Bozkurtlar,

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma Thomas Schneider,

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer Shinjiro.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer–Specific Death in Squamous Cell Carcinoma Shaohua Lu, MD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient Jong Sik Lee, MD, Jae Young Hur, PhD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung Zhigang.

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis Annemarie T. Fernandes, BA, Eric.

Sclerosing Pneumocytoma with Lymph Node Metastasis

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Asishana A. Osho, MD, MPH, Christopher J

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy Apar Pataer, MD, PhD, Neda Kalhor,

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma Thomas Schneider,

Meghan Campo, MD, David Gerber, MD, Justin F. Gainor, MD, Rebecca S

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

“Pseudoprogression” of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy Kentaro Ito, MD, Osamu Hataji, MD, Koji Katsuta, MD, Tetsu Kobayashi,

Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non–Small Cell Lung Cancer in the U.S. National Cancer Data Base

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Tumor Spread through Air Spaces Affects the Recurrence and Overall Survival in Patients with Lung Adenocarcinoma >2 to 3 cm Chenyang Dai, MD, Huikang.

Explore the Radiotherapeutic Clinical Target Volume Delineation for Thoracic Esophageal Squamous Cell Carcinoma from the Pattern of Lymphatic Metastases

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

Stromal Macrophage Expressing CD204 is Associated with Tumor Aggressiveness in Lung Adenocarcinoma Yoichi Ohtaki, MD, Genichiro Ishii, MD, PhD, Kanji.

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Multiple Primary Cancers or Multiple Metastases, That Is the Question

It’s All in the “Swerve of the Curve”

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

Pneumonectomy After Chemoradiation Therapy for Non-Small Cell Lung Cancer: Does “Side” Really Matter? Anthony W. Kim, MD, L. Penfield Faber, MD, William.

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions Mauricio Burotto, MD, Anish Thomas, MD, Deepa Subramaniam,

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases Hironori Uruga, MD, PhD, Emine Bozkurtlar, MD, Tiffany G. Huynh, BA, Alona Muzikansky, MA, Yasushi Goto, MD, PhD, Maria Gomez- Caraballo, BA, Aaron N. Hata, MD, PhD, Justin F. Gainor, MD, Eugene J. Mark, MD, Jeffrey A. Engelman, MD, PhD, Michael D. Lanuti, MD, Mari Mino-Kenudson, MD Journal of Thoracic Oncology Volume 12, Issue 3, Pages 458-466 (March 2017) DOI: 10.1016/j.jtho.2016.10.015 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 (A and B) An example of lung adenocarcinoma exhibiting membranous expression of programmed death ligand 1 on the vast majority of tumor cells. Original magnification, ×100 (A) and ×200 (B). (C and D) CD8-positive tumor-infiltrating lymphocytes are semiquantitatively evaluated on the tumor cells (arrow), in the interstitial stroma (arrow head) (C), and in the stroma at the tumor border (arrow) (D). Original magnification, ×100 (C and D). Journal of Thoracic Oncology 2017 12, 458-466DOI: (10.1016/j.jtho.2016.10.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Kaplan-Meier plot for the entire cohort (A) and the cohort treated with adjuvant therapy (B) stratified by programmed death ligand 1 (PD-L1) expression status with use of a 1% cutoff. Journal of Thoracic Oncology 2017 12, 458-466DOI: (10.1016/j.jtho.2016.10.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1 A&B: An example of lung adenocarcinoma exhibiting PD-L1 expression in 1% of tumor cells. The PD-L1 expression on the tumor cells (arrows in B) is limited to the area immediately adjacent to inflammatory cells that also show PD-L1 expression (circle in B). Similar foci are seen in a scattered manner throughout the entire tumor in this case. Journal of Thoracic Oncology 2017 12, 458-466DOI: (10.1016/j.jtho.2016.10.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2 Correlation of PD-L1 expression between the primary tumor and N1 lymph node (A), between the primary tumor and N2 lymph node (B), and between N1 and N2 lymph nodes (C). Journal of Thoracic Oncology 2017 12, 458-466DOI: (10.1016/j.jtho.2016.10.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 3 A&B: An example of lung adenocarcinoma in which the primary tumor (A) exhibits predominant papillary pattern and no PD-L1 expression, while metastatic deposits in the N1 lymph node (B) show solid pattern and PD-L1 expression on all tumor cells and surrounding histiocytes (A&B: x200). C&D: Another example of adenocarcinoma with predominant acinar pattern and PD-L1 expression on 5% of the tumor cells in both the primary tumor (C) and N1 lymph node (D) (C&D: x200). Journal of Thoracic Oncology 2017 12, 458-466DOI: (10.1016/j.jtho.2016.10.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 4 Kaplan-Meier plot for the entire cohort (A) and the cohort treated with adjuvant therapy (B) stratified by PD-L1 expression status with using 5% cut-off. Journal of Thoracic Oncology 2017 12, 458-466DOI: (10.1016/j.jtho.2016.10.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 5 Kaplan-Meier plot for the entire cohort (A) and the cohort treated with adjuvant therapy (B) stratified by PD-L1 expression status with using 50% cut-off. Journal of Thoracic Oncology 2017 12, 458-466DOI: (10.1016/j.jtho.2016.10.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions